24 results
P
women with ER-positive/HER2-negative early breast cancer
I/C
neoadjuvant endocrine therapy (NET), high Ki-67 index after NET vs. low Ki-67 index after NET
O
recurrence-free survival (RFS) and overall survival (OS)
P
patients with colorectal neoplasms
I/C
endoscopic resection (ER), primary or additional surgery
O
overall survival, disease-specific survival, recurrence-free survival at 5 years, recurrence, metastasis
P
1042 participants with primary shoulder dislocation
I/C
External immobilization (ER), Internal immobilization (IR)
O
Recurrence rates, Complications, Compliance rate
P
patients with ER-positive, HER2-negative breast cancer
I/C
neoadjuvant chemotherapy, high recurrence score vs. low-intermediate score
O
pathological complete response (pCR)
P
patients with oestrogen-receptor-positive (ER+) breast cancer
I/C
radiomics MRI tumour analyses, OncotypeDX® recurrence score (RS)
O
differentiating patients into clinically relevant subgroups for prognostication and therapeutic decision making
P
infertile women with poor endometrial receptivity (PER)
I/C
acupuncture, different acupuncture dosages
O
endometrium receptivity (ER) parameters by transvaginal sonography (TVS) and subsequent pregnancy outcomes
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
breast cancer patients
I/C
tumor budding, high-grade vs. low-grade tumor budding
O
lymph node metastasis, lymphovascular invasion, ER, PR, HER2neu, KI67, and molecular subtype triple-negative breast carcinoma
P
breast cancer
I/C
MAGE-C gene expression, tumor grade, lymph node metastasis, tumor type, tumor stage, ER expression, HER-2 expression, tumor embolus
O
overall survival, recurrence-free survival, metastasis-free survival
P
COVID-19 patients
I/C
Qingfei Paidu decoction (QFPDD) combined with Western medicine treatments (WMT), control arm
O
aggravation rate (AR), effective rate (ER), duration of viral shedding, length of hospital stay, incidence of adverse events (AE)